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Abstract
Background: Simvastatin reduces cardiovascular mortality and morbidity but, as with other
HMG-CoA reductase inhibitors, can cause significant muscle toxicity and has been associated with
elevations of liver transaminases.
Methods:  Muscle and liver adverse effects of simvastatin 40 mg daily were evaluated in a
randomized placebo-controlled trial involving 20,536 UK patients with vascular disease or diabetes
(in which a substantial reduction of cardiovascular mortality and morbidity has previously been
demonstrated).
Results: The excess incidence of myopathy in the simvastatin group was < 0.1% over the 5 years
of the trial, and there were no significant differences between the treatment groups in the incidence
of serious hepatobiliary disease.
Conclusion: Among the many different types of high-risk patient studied (including women, older
individuals and those with low cholesterol levels), there was a very low incidence (< 0.1%) of
myopathy during 5 years treatment with simvastatin 40 mg daily. The risk of hepatitis, if any, was
undetectable even in this very large long-term trial. Routine monitoring of liver function tests
during treatment with simvastatin 40 mg is not useful.
Trial Registration: ISRCTN48489393
Background
The HMG-CoA reductase inhibitor simvastatin is widely
used to lower LDL cholesterol and reduce cardiovascular
risk[1]. The substantial reductions in cardiovascular mor-
bidity and mortality produced by lowering blood choles-
terol with simvastatin were established first in
hypercholesterolaemic patients with coronary heart dis-
ease (CHD)[2], and subsequently by the Heart Protection
Study (HPS) and other trials, in a broad range of high risk
patients with and without hypercholesterolaemia or CHD
[3-7]. Large long-term randomized trials can provide val-
uable information on clinically relevant adverse effects of
drugs that are too uncommon to be evaluated in the
smaller, relatively short-term, trials upon which regula-
tory approval is typically based. The tolerability of simvas-
tatin early in HPS has been reported[8], and the safety
further summarised in the first report of results[3]. The
lack of any detectable effect of simvastatin on the risk of
non-cardiovascular mortality, haemorrhagic stroke, can-
cer, respiratory and neurological morbidity, and the lack
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of hazard in patients with diabetes or heart failure, as well
as those with low blood cholesterol, have been reported
in subsequent papers[4,5,9,10]. In this paper, we provide
further detail about the effects on muscle and liver adverse
events in HPS.
Since their introduction in the 1980s, statins have been
recognised to have occasional adverse effects on muscle
and liver, with the former of greater clinical importance.
Few drugs have toxic effects on skeletal muscle, but all
statins occasionally cause myopathy [11-13]. In this con-
text, myopathy is generally defined as unexplained muscle
pain or weakness accompanied by a creatine kinase (CK)
level >10 times the upper limit of normal (ULN)[11,14].
Rhabdomyolysis is a severe form of myopathy (typically
with CK >40 × ULN) that may require the patient to be
hospitalised, often associated with myoglobinuria that
can lead to acute renal failure and death. Though rare with
all currently marketed statins, this adverse effect has been
the focus of increased concern as a result of the with-
drawal of cerivastatin by its manufacturer in 2001 due to
a high incidence of rhabdomyolysis[15].
Treatment with lipid lowering therapy, including statins,
tends to increase hepatic transaminases, but clinical hep-
atitis is uncommon during statin therapy[16,17]. Routine
monitoring of liver function has been recommended in
the prescribing information for all statins, but its useful-
ness has subsequently been questioned[16,18]. The size,
duration and placebo control of HPS provides the oppor-
tunity to assess clinical and biochemical adverse effects on
muscle and liver during treatment with simvastatin 40 mg
daily, and to use this information to evaluate the value of
routine monitoring of liver function tests.
Methods
Details have been reported previously[3-6,8-10] (see also
http://www.ctsu.ox.ac.uk/projects/hps/index_html) and
are summarised below. The study was carried out in
accordance with the principles of the Declaration of Hel-
sinki and had ethics approval from Local Research Ethics
Committees at each of the study sites (the study com-
menced prior to the advent of Multicentre Research Ethics
Committees in the UK).
Recruitment and follow-up
The HPS participants were men and women aged 40 to 80
years at high risk of cardiovascular events because of
occlusive arterial disease; or diabetes mellitus; or, if male
and ≥65 years, treated hypertension. People were ineligi-
ble if: their blood total cholesterol was <3.5 mmol/L (135
mg/dL); their own doctor considered statin therapy to be
clearly indicated or contraindicated; they had suffered a
stroke, myocardial infarction or hospitalisation for angina
pectoris within the previous 6 months; they had chronic
liver disease or evidence of abnormal liver function (see
footnote to Table 1); severe renal disease or evidence of
substantially impaired renal function (Table 1); inflam-
matory muscle disease or evidence of muscle problems;
concurrent treatment with ciclosporin, fibrates or lipid-
modifying (>1 g daily) doses of niacin; child-bearing
potential; severe breathlessness (e.g. due to heart failure
or COPD); life-threatening conditions other than vascular
disease or diabetes (including any cancer except non-
Table 1: Reasons for patients who entered the run-in period not proceeding to the Randomisation appointment
Reason Phase of Run-in period
Placebo Active Unknown Overall
Screening blood results 1132 - - 1132
Cholesterol <3.5 mmol/L 220 - - 220
Liver function test abnormality* 656 - - 656
CK>3 × ULN 78 - - 78
Creatinine >200 μmol/L 192 - - 192
Participant vetoed or advised against by patient's physician 797 577 1 1375
Randomisation appointment cancelled 1100 1139 296 2535
MI, angina or stroke during run-in 7 24 0 31
Died or cancer diagnosed 18 29 2 49
Myopathy 02 0 2
Other adverse event 193 217 0 410
Patient wishes 854 848 0 1702
Other or unknown reason 28 19 294 341
Failed to attend randomisation appointment (no reason given) 0 0 3129 3129
Any of the above 3029 1716 3426 8171
*ALT >1.5 × ULN, or >1.0 = 1.5 × ULN and AST, GGT or ALP >2 × ULN or any of AST, GGT or ALP >4 × ULN.BMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
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melanoma skin cancer); or any other condition that might
limit long-term compliance.
At the initial Screening visit, patients who appeared eligi-
ble for the trial were provided with a written description
of the study and, if agreeing to participate, their informed
consent sought[8]. Eligible and consenting patients had a
non-fasting blood sample taken and entered a pre-rand-
omization "run-in" treatment phase involving 4 weeks of
placebo followed by 4–6 weeks of simvastatin 40 mg
daily. In addition to blood lipids, CK, creatinine, alanine
transaminase (ALT) and gamma-glutamyl transferase
(GGT) were routinely measured by the central laboratory
in the blood that had been collected at the screening visit
(i.e., immediately before entering the run-in period and
before any active statin treatment was started). Samples
from participants with ALT >1.0 ≤ 1.5 × ULN or GGT >2 ×
ULN at the screening visit were also assayed for aspartate
transaminase (AST) and alkaline phosphatase (ALP).
Patients who entered run-in had their study treatment
stopped during the placebo phase, and were not to be ran-
domized, if their screening visit blood sample showed: (i)
ALT >1.5 × ULN; (ii) ALT >1 ≤ 1.5 × ULN and GGT, AST,
or ALP >2 × ULN; (iii) GGT, AST, or ALP >4 × ULN; or (vi)
CK >3 × ULN, creatinine >200 μmol/L or total cholesterol
<3.5 mmol/L.
As well as allowing the biochemical eligibility to be
checked, the run-in period was intended to increase the
likelihood that those subsequently randomized would
continue taking their allocated study treatment for an
extended period. In particular, participants for whom
their own doctors considered statin therapy to be clearly
indicated or clearly contraindicated after being provided
with information about their patient's lipid levels at
screening were not to be randomized. Also, patients who
had (or felt they had) any adverse effects, appeared to be
non-compliant or wished to drop out for any reason dur-
ing run-in were not to be randomized. The use of simvas-
tatin during run-in also allowed an indirect randomized
comparison of post-randomization outcomes in partici-
pants who appeared to have a large cholesterol-lowering
response to simvastatin versus those with a small response
between the screening and randomization visits[3].
Participants were randomly allocated to receive simvasta-
tin 40 mg daily or matching placebo tablets for about 5
years (and separately, using a 2 × 2 factorial design, to
receive antioxidant vitamins or matching placebo cap-
sules[19]). Randomized participants were to be seen at 4,
8 and 12 months, and then 6-monthly (with follow-up by
telephone to individuals who did not attend or, alterna-
tively, via their general practitioners). Blood samples were
taken from all participants at each follow-up visit for cen-
tral laboratory assay of ALT and, in any participant report-
ing unexplained muscle symptoms or concomitant use of
a non-study statin, of CK[8]. At each follow-up visit, par-
ticipants were explicitly asked by the study nurse about all
episodes of unexplained muscle pain or weakness (inde-
pendent of any attribution to study treatment) that had
occurred since their previous visit. Information was also
recorded at each follow-up visit about any suspected myo-
cardial infarction, stroke, vascular procedure, cancer or
other serious adverse event (including all hospital admis-
sions). A serious adverse event (SAE) was defined as any
new or worsening adverse condition that was fatal or life-
threatening, or resulted in or prolonged inpatient hospi-
talization, or caused significant or persistent disability.
Myopathy was considered to be a SAE irrespective of
whether it resulted in hospital admission. Non-serious
adverse experiences other than muscle symptoms were
only recorded if they were a reason for stopping study
medication.
If any SAEs were considered by the participant, study
nurse or managing clinician to be possibly drug-related,
or if there were potentially serious abnormalities in any
safety blood tests, the participant was advised, at least
temporarily, to stop the relevant study treatment. The pro-
tocol defined the following algorithms for the assessment
of possible muscle or liver abnormalities during follow-
up:
Potential muscle toxicity
Symptoms of myopathy (i.e., new unexplained muscle
pain or weakness accompanied by an otherwise unex-
plained elevation of CK >10 × ULN[14]) would result in
the study treatment (simvastatin or placebo tablets) being
stopped permanently (with 3-week follow-up visits until
CK reverted to normal, i.e. ≤ 3 × ULN). Creatine kinase >4
× ULN but ≤ 10 × ULN that could not be explained (e.g.
by some trauma, intramuscular injection, heavy exercise,
recent MI) was to be checked within about 1 week and, if
repeat CK was >4 × ULN, then study treatment would be
stopped temporarily. CK was to be checked again in about
6 weeks and study treatment stopped permanently if still
>3 × ULN. If, on the other hand, CK was ≤ 3 × ULN, then
the allocated study treatment would be started again, with
2 further early recall visits at 3-week intervals at which CK
must remain ≤ 3 × ULN, otherwise the study treatment
was to be stopped permanently.
Abnormality of liver function tests
ALT >4 × ULN was to be checked within about 1 week,
while ALT >2 × ULN but ≤ 4 × ULN was to be checked
within about 3 weeks. If the repeat ALT was >4 × ULN,
then study treatment was to be stopped temporarily;
whereas if it was >2 but ≤ 4 × ULN, ALT was to be checked
again in about 3 weeks, with study treatment then
stopped temporarily only if ALT remained >2 × ULN. After
stopping study treatment temporarily, ALT was to be
checked again in about 6 weeks and study treatmentBMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
Page 4 of 10
(page number not for citation purposes)
stopped permanently if still >1.5 × ULN (with 3-week fol-
low-up visits until ALT reverted to normal, i.e., ≤ 1.5 ×
ULN). If, on the other hand, ALT was ≤ 1.5 × ULN, then
the allocated study treatment would be started again, with
2 further early recall visits at 3-week intervals at which ALT
must remain ≤ 2 × ULN, otherwise the study treatment
was to be stopped permanently.
Statistical analyses
Differences in proportions of those allocated simvastatin
versus those allocated placebo were assessed using stand-
ard parametric methods and an intention-to-treat
approach. No adjustment has been made for multiple
hypothesis testing, but due allowance is made in the inter-
pretation of the results.
Role of the funding sources
The investigators were responsible for the study design,
data collection, data analysis, data interpretation, and
writing of the report, independently of all funding
sources.
Results
Pre-randomization run-in period
Between July 1994 and May 1997, 63,603 people were
screened in 69 UK study clinics. Of these, 32,145 patients
entered the pre-randomization run-in period, and 20,536
patients were randomized. Reasons for not entering the
run-in period have been reported previously[8]. Of those
entering the run-in period, 8171 withdrew during the run-
in period phase (Table 1) and a further 3438 attended the
randomization visit but were not randomized (Table 2).
Among the 8171 people who dropped out before the ran-
domization visit, 1132 were excluded per protocol by
their screening blood results and, in a further 1375 cases,
the patient's physician (either their general practitioner or
the local HPS collaborator) directly advised the coordinat-
ing centre or patient against proceeding to randomiza-
tion. By far the most common reason (73%) for this
advice was that lipid-lowering treatment was considered
indicated. The randomization visit was cancelled by or on
behalf of 2535 patients, and a further 3129 failed to
appear for their scheduled randomization visit. Table 1
provides the reasons for dropping out before the rand-
omization appointment subdivided by whether the report
was made during the 4 week placebo or 4–6 week active
phase of the run-in period. It should be noted that the pla-
cebo/active categorization is based on the date that the
patient or their doctor informed the clinic or coordinating
centre that they would not be continuing in the study. The
actual date of any adverse event was not recorded. As the
date of any such event would often be earlier (and obvi-
ously could not have been later) than the report leading to
discontinuation, there is a bias in Table 1 towards more
patients with adverse events being categorized in the
active phase. Nevertheless, the numbers of patients drop-
ping out are generally similar in both phases, notably for
reported adverse events.
Two of 32,145 patients who entered the run-in period
developed myopathy while taking simvastatin and did
not proceed to randomization. One of them was hospital-
ized with worsening renal failure, but both patients recov-
ered. In addition, one patient had a serious rectal bleed
during run-in which was attributed to an interaction
between simvastatin and his anti-coagulation medication
leading to a high international normalised ratio (INR).
Other than these 3 patients, none of the 410 patients
(Table 1) in the "other adverse event" category had a SAE
attributed to study simvastatin. These "other adverse
events" were predominantly relatively minor (e.g. gas-
trointestinal symptoms) but might have compromised
long-term adherence to study medication.
Table 2 shows the reasons for not proceeding to randomi-
zation among patients attending the randomization visit.
Among these 3438 participants, the most common reason
(87%) for not being randomized was personal choice or
problems with long-term attendance or compliance.
Again, the "other adverse events" recorded were generally
minor and most probably not attributable to treatment.
For example, although 531 of these patients (2.2%)
reported new unexplained muscle symptoms in response
to an explicit enquiry (and after having been advised in
the information material that simvastatin could cause
muscle pain or weakness), so too did about 6% of the par-
ticipants subsequently randomized to receive either simv-
astatin or placebo at every visit during follow-up (see
below).
Randomization and follow-up
A total of 15,454 men (75%) and 5082 women were ran-
domized. Mean age at study entry was 64.0 years (SD 8.4),
with 5806 aged at least 70 years. The mean duration of fol-
low-up was 5.0 years for all randomized participants: 5.3
years for those who survived to the scheduled end of study
treatment and about half that for those who did not
Table 2: Reasons for withdrawal of patients in the run-in period 
who attended their Randomisation appointment
Reason Overall
Cancer diagnosed during run-in 28
MI, stroke or hospitalisation for angina during run-in 94
Lipid-lowering drug started 271
New unexplained muscle symptoms 531
Other adverse event 161
Patient wishes or long-term adherence in doubt 2992
Patient's physician discouraged participation 25
Other reasons 135
Any of the above 3438BMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
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(yielding 51,121 person years of follow-up for all those
allocated simvastatin and 50,664 for all those allocated
placebo). Baseline characteristics, compliance with study
medication and changes in blood lipid levels have been
presented previously [3-6].
During follow-up, only serious adverse events were rou-
tinely recorded, and many such events were study end-
points (such as major vascular events or malignancies),
which have been reported previously[3-6,9,10]. Only 16
patients (9 allocated simvastatin versus 7 allocated pla-
cebo) were considered by their managing doctors, before
unblinding, to have had SAEs possibly related to study
simvastatin (Table 3). All of those patients had their study
treatment stopped as a result. The cases of myopathy,
muscle symptoms and hepatitis are discussed below, the
GI haemorrhage was later attributed to colon cancer, and
the 2 men who developed peripheral neuropathy (one
later thought to be due to a lymphoma) were both on pla-
cebo.
Effects on muscle
Following randomization, 7 patients in the simvastatin
group and 2 in the placebo group developed myopathy
that was attributed to study treatment before unblinding
(Table 3). Among the 7 patients in the simvastatin group,
4 were also taking CYP3A4 inhibitors (2 on erythromycin
and 2 on verapamil), and one other had chronic renal fail-
ure and diabetes. Another of these patients started to take
non-study simvastatin 20 mg daily about 4 years after ran-
domization in addition to the study simvastatin 40 mg
daily (i.e. a total dose of 60 mg daily) and developed
myopathy 12 months later. Four of these 7 patients had
CK >10,000 U/L, and were considered to have rhabdomy-
olysis; none developed organ damage but one patient's
chronic renal failure worsened. Five of the 7 patients were
hospitalized, 1 primarily for angina and 2 with other seri-
ous medical conditions (metastatic colon cancer; major
urinary tract infection) that were at least partial causes of
the hospitalization. All recovered from their myopathy,
either after simvastatin was stopped or, in one case, after
erythromycin was discontinued. Of the 2 myopathy cases
in the placebo group that were attributed to study treat-
ment, one was taking a non-study statin (cerivastatin 0.3
mg daily) in addition to their study treatment. The other
placebo-allocated patient developed rhabdomyolysis
after being given streptokinase for acute MI and went on
to develop progressive renal failure and die after a second
MI approximately 4 weeks later. An additional patient in
the placebo group developed severe muscle symptoms
which were considered serious and attributed to study
treatment, but this was associated with a maximum meas-
ured CK of only about 5 × ULN (i.e. did not meet the pre-
specified definition of myopathy).
Three additional patients allocated simvastatin and two
allocated placebo developed myopathy or rhabdomyoly-
sis that was not attributed to study treatment, perhaps
because they had atypical features that made a casual rela-
tionship appear less plausible. Among the 3 patients allo-
cated simvastatin, one developed muscle pain and
weakness following a colectomy for colon cancer, but CK
>10 × ULN was only detected 2 months later at the next
scheduled visit when he was asymptomatic. Rhabdomyol-
ysis was recorded on the post-mortem report (which gives
coronary heart disease as the cause of death) of another
patient who died following major surgery, but it is not
known whether he was still taking the allocated simvasta-
tin at that time. The third patient developed a deep vein
thrombosis and thigh pain accompanied by raised CK
(6800 IU/L), which was thought to be caused by fat
emboli, one day after receiving tissue plasminogen activa-
tor followed by coronary angioplasty for acute MI. It is not
known whether he was taking the allocated simvastatin at
the time, but he later continued study treatment without
further problems. Of the two placebo-allocated patients
with myopathy not attributed to study treatment, one was
hypothyroid and the other developed an acute compart-
ment syndrome and rhabdomyolysis following resuscita-
tion from a cardiac arrest.
Based on the randomized comparison, the overall inci-
dence of myopathy irrespective of whether or not it was
attributed to treatment was 0.1% (10 cases) among simv-
Table 3: Serious adverse events considered (before unblinding) to be probably due to study simvastatin
Event Simvastatin-allocated Placebo-allocated
(n = 10269) (n = 10267)
Myopathy/rhabdomyolysis* 7 (0.1%) 2 (0.0%)
Muscle pain/weakness** 0 (0.0%) 1 (0.0%)
Hepatitis 1 (0.0%) 1 (0.0%)
GI haemorrhage 1 (0.0%) 0 (0.0%)
Renal failure 0 (0.0%) 1 (0.0%)
Neurological 0 (0.0%) 2 (0.0%)
* Includes 1 patient in each group taking non-study statin in addition to study treatment
** CK <10 × ULNBMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
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astatin-allocated patients versus 0.04% (4 cases) among
placebo allocated patients, yielding an excess incidence of
0.06% over 5 years with allocation to simvastatin 40 mg
daily. Muscle symptoms not caused by myopathy were
very common, with no significant between-group differ-
ences: at each visit, muscle pain or weakness was reported
on direct questioning by about 6% of patients allocated
simvastatin and by about 6% of patients allocated pla-
cebo, with 33% of patients in each treatment group
reporting muscle symptoms at least once during the study.
Effects on liver
Following randomization, 1 patient in the simvastatin
group and 1 in the placebo group developed hepatitis
(both with jaundice but of unclear aetiology) that was
attributed to study treatment before unblinding (Table 3).
The patient allocated simvastatin was found to have ALT
of 257 U/L (ULN 45 U/L) at 7 months after randomiza-
tion, and simvastatin was then discontinued. The ALT
remained elevated, and 16 months after randomization
he was admitted to hospital with severe acute hepatitis
(ALT >1000 U/L, AST = 1728 U/L [ULN 42 U/L] and
bilirubin = 459 μmol/L [ULN 17 μmol/L]). Liver biopsy
showed acute hepatitis with confluent necrosis, which the
reviewing pathologist considered more typical of viral
hepatitis than drug-induced hepatotoxicity (although
viral serology and hepatic autoantibody tests were nega-
tive). The patient gradually recovered hepatic function
and returned to work, although transaminases remained
elevated. The case of hepatitis in the placebo group that
was attributed to study treatment was subsequently found
to have septicaemia.
Excluding primary or secondary hepatic malignancies
(reported elsewhere[9]), there were about 200 patients in
each group with liver-related SAE's. The large majority
were due to biliary disease (178 [1.73%] simvastatin vs
179 [1.74%] placebo), predominantly gallstones. A total
of 6 cases of hepatitis occurred in the simvastatin group
and 9 in the placebo group (including the 2 cases dis-
cussed above). Ten of these patients continued their allo-
cated study treatment after hepatitis developed, 2 stopped
it for other reasons prior to the hepatitis, and 3 stopped it
due to raised liver enzymes (i.e. the 2 cases considered to
be due to study treatment, and a further patient with hep-
atitis C). It is worth noting that there were no specific
exclusion criteria from HPS related to alcohol consump-
tion.
On routine monitoring at each follow-up visit, ALT >3 ×
ULN (i.e. the "traditional" cut-point for a significant
transaminase elevation[20]) was found in 77 patients
allocated simvastatin and 65 allocated placebo (0.75% vs
0.63%; P = 0.35) on at least one occasion during an aver-
age of 5 years of follow-up. There appeared to be a signif-
icant difference between the treatment groups early after
randomization: at the first (4 month) follow-up visit, ALT
>3 × ULN was found in 17 simvastatin vs 4 placebo
patients (0.17% vs 0.04%; P < 0.01). Such ALT elevations
were re-checked according to the pre-specified algorithm
described above. Most of these elevations were not con-
firmed at these early recall visits despite continued treat-
ment: overall, ALT >3 × ULN on repeat testing was found
in only 21 patients in the simvastatin group compared to
9 in the placebo group (0.20% vs 0.09%; P = 0.045); and
of these, only 1 vs 0 were diagnosed clinically as hepatitis.
Of the elevations detected at the first follow-up visit, 8 vs
0 were confirmed on repeat testing, but none developed
liver disease. Six of these 8 were permanently discontin-
ued from treatment according to the study algorithm, so it
is not known whether they would have developed clini-
cally apparent liver toxicity had they continued taking
simvastatin.
Reasons for stopping allocated simvastatin or placebo
Compared to the simvastatin group, more patients in the
placebo group stopped taking study medication (33.5%
vs 43.1%; p < 0.0001: Table 4). This difference was chiefly
attributable to more patients allocated placebo starting a
non-study statin (3.5% vs 13.6%; p < 0.0001), with very
similar numbers of patients stopping for other reasons
(28.3% simvastatin vs 27.8% placebo; p = 0.45). Discon-
tinuation was recorded by the clinic nurses as being due to
liver or muscle enzyme abnormalities in 57 patients in the
simvastatin group and 46 patients in the placebo group (P
= 0.32). Such discontinuations could result either from
application of the protocol-defined algorithms for liver
function test or CK abnormalities measured within the
study, or from enzyme abnormalities detected outside the
study. Because this reason for stopping was recorded using
a single check box on the clinic form, it is not possible
unequivocally to separate the liver versus muscle enzyme
abnormality discontinuations. However, it has been pos-
sible to subdivide these patients using retrospectively
defined cut-points of CK (>4 × ULN), ALT (>1.5 × ULN)
and GGT (>2 × ULN) measured during their previous 4
study visits. Using these cut-points, muscle enzymes were
elevated (with or without elevated liver enzymes) in 11
simvastatin versus 2 placebo patients (0.11% vs 0.02%; P
= 0.03), liver enzymes alone were elevated in 42 versus 36
(0.41% vs 0.35%; P = 0.57), and neither were elevated in
4 vs 8. Five simvastatin vs 0 placebo patients had study
treatment stopped with CK >4 × ULN recorded at one or
more of these previous visits but without achieving the cri-
teria for a diagnosis of myopathy (i.e. CK >10 × ULN with
unexplained muscle pain or weakness).
Discussion
The randomization and systematic follow-up of over
20,000 patients in HPS has allowed the reliable placebo-BMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
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controlled assessment of the clinical and biochemical
effects on muscle and liver of about 5 years of simvastatin
40 mg daily. It provides further evidence of the safety of
this treatment regimen, with an incidence of myopathy
that was less than 0.1% over 5 years. Simvastatin 40 mg
daily did produce an excess of ALT >3 × ULN of about
0.1% in the first few months after randomization, but
there was no evidence that this resulted in subsequent
liver disease. Prior to randomization, many potential
drop-outs were excluded during the run-in period or at the
randomization visit in order to improve the statistical sen-
sitivity of HPS to assess the efficacy of prolonged simvas-
tatin [21]. The pre-randomization run-in period involved
4 weeks of treatment with placebo simvastatin followed
by 4–6 weeks of simvastatin 40 mg daily (with the active
antioxidant mixture given throughout the run-in period),
which raises questions about the generalisability of the
safety analyses because patients may have withdrawn dur-
ing the run-in due to adverse effects caused by simvastatin.
The potential impact of the run-in period on the assess-
ment of safety in HPS is considered below.
Effects on muscle
Approximately one third of the randomized participants
reported muscle symptoms at some time during follow-
up, but there were no significant differences between the
treatment groups at any time or when subdivided by age,
gender or pre-existing disease. This high rate of reported
muscle symptoms may reflect a high background rate of
musculoskeletal problems in middle and old age (mean
age of the study population was 64 at randomization), but
it may also reflect the advice given during the informed
consent process that simvastatin can cause muscle pain
and weakness which was reinforced by regular direct ques-
tioning at each follow-up visit. Using the pre-specified
definition for myopathy (i.e. unexplained muscle pain or
weakness accompanied by CK >10 × ULN[11,14]) there
were 10 (0.10%) cases among patients randomly allo-
cated simvastatin 40 mg daily and 4 (0.04%) cases in the
placebo group (not all of which was attributed to study
treatment). This difference is not statistically significant,
but – given that myopathy is a well-established adverse
effect of simvastatin (and of other statins, particularly at
higher doses [15,22]) and the cases in the placebo group
had predisposing factors – it is likely that some of this
excess was caused by simvastatin.
Among 32,145 patients who started the run-in period for
HPS, only 0.2% (78) of patients with CK >3 × ULN in
blood collected at the screening visit were withdrawn dur-
ing the placebo phase, and the impact of their exclusions
seems likely to be small. During the active run-in phase on
simvastatin, 2 (< 0.01%) cases of myopathy were
recorded. One of these patients was attending a renal
clinic for pre-existing renal impairment which was an
exclusion criterion since it can pre-dispose to myopa-
Table 4: Reasons for randomised patients stopping study simvastatin/placebo tablets
Reason(s) given Simvastatin-allocated
(n = 10269)
Placebo-allocated
(n = 10267)
Patient wishes 2186 (21.3%) 2113 (20.6%)
Unable or unwilling to attend clinic 757 (7.4%) 745 (7.3%)
Non-study statin started 364 (3.5%) 1401 (13.6%)
Other contraindicated drug started 11 (0.1%) 50 (0.5%)
Poor compliance 88 (0.9%) 120 (1.2%)
Raised liver or muscle enzymes** 57 (0.6%) 46 (0.4%)
Raised liver enzymes 46 (0.4%) 36 (0.4%)
Raised muscle enzymes 11 (0.1%) 2 (0.0%)
Muscle pain or weakness 60 (0.6%) 62 (0.6%)
Medical advice 158 (1.5%) 206 (2.0%)
Medical diagnosis/treatment/investigation 143 (1.4%) 160 (1.6%)
Non-specific adverse events 110 (1.1%) 126 (1.2%)
Other adverse events 229 (2.2%) 225 (2.2%)
Gastrointestinal 114 (1.1%) 104 (1.0%)
Psychological/psychiatric 49 (0.5%) 54 (0.5%)
Rash or skin 22 (0.2%) 22 (0.2%)
Neurological 10 (0.1%) 14 (0.1%)
Other 44 (0.4%) 43 (0.4%)
Other or family reasons 149 (1.5%) 141 (1.4%)
Any of the above* 3440 (33.5%) 4424 (43.1%) P = 0.0000
* Patient may stop study treatment for more than one reason
** Includes 6 vs 2 myopathy cases (the remaining myopathy patients had no further visits) and 2 vs 1 hepatitis casesBMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
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thy[22]. Patients were asked about muscle symptoms at
the randomization visit and were not to be randomized if
they reported new unexplained muscle pain. But, given
the lack of difference between the simvastatin and placebo
groups in post-randomization reports of muscle symp-
toms, it seems unlikely that exclusion of the 531 patients
who reported new unexplained muscle pain (2.2% of
those attending) at their randomization visit would have
materially reduced the subsequent incidence of statin-
induced myopathy. Moreover, HPS still provides a com-
pletely unbiased assessment of the risk of myopathy with
simvastatin 40 mg daily during 5 years of treatment
among patients who present with CK <3 × ULN and can
tolerate treatment for about one month. In that regard,
HPS reflects real-life since the incidence of myopathy in
patients who do not (or believe they do not) tolerate the
drug, and so will not be exposed to long-term therapy, is
moot.
Effects on liver
Prescribing information for simvastatin (and other stat-
ins) has typically recommended routine liver function
monitoring, even though – despite over 20 years of clini-
cal investigation and widespread use – there is still no
good evidence that the drug is hepatotoxic. There is no
question that statin therapy can increase blood concentra-
tions of hepatic transaminases, but it has never been
shown that such increases progress to clinical hepatitis if
treatment continues. Moreover, these statin-induced
transaminase elevations are not accompanied by increases
in bilirubin, which the US Food and Drug Administration
(FDA) considers to be the hallmark of a drug likely to pro-
duce significant liver toxicity[20]. Furthermore, all drugs
that reduce LDL cholesterol levels appreciably (including
bile acid sequestrants, which are not absorbed, and
ezetimibe) produce small increases in the blood levels of
transaminases[16], suggesting that the increases seen with
simvastatin and other statins are (at least in part) a sec-
ondary effect of lowering LDL cholesterol.
Following randomization in HPS, hepatitis was recorded
in a total of 6 patients allocated simvastatin and 9 allo-
cated placebo during an average of 5 years of follow-up.
Hence there was no significant evidence that simvastatin
40 mg daily materially increased the risk of clinical hepa-
titis. Liver function monitoring during HPS was intensive,
with ALT (which is considered to be most sensitive to sta-
tin-induced changes[20]) measured at every visit, so it
cannot be proved that such monitoring did not prevent
some patients from proceeding to hepatitis. But, this
seems unlikely to have had much impact, since there was
only a small difference between the treatment groups in
ALT >3 × ULN at the first 4 month follow-up visit (17
[0.17%] simvastatin vs 4 [0.04%] placebo) and no appar-
ent difference thereafter. Similarly, among the 4444
patients in the Scandinavian Simvastatin Survival Study
(4S), there was only a small difference between the treat-
ment groups in ALT >3 × ULN which was confined to the
first year of treatment (20 [0.90%] allocated simvastatin
20–40 mg daily vs 8 [0.36%] allocated placebo)[23]. By
contrast, drugs that are hepatotoxic typically produce
marked transaminase elevations at a rate that is much
higher than the incidence of clinical hepatitis[24].
Irrespective of whether the ALT elevations in HPS
occurred early or late following randomization, most were
not found to have persisted on repeat testing despite con-
tinuation of the simvastatin treatment, suggesting that
they are not likely to reflect a clinically relevant adverse
drug effect. Whether the residuum of persistent elevations
has any clinical meaning is uncertain, but the absolute
excess of patients discontinued due to liver enzyme
abnormalities in HPS was very small (about 1 per 1000)
and not statistically significant. A comparably small, and
non-significant, excess of study treatment discontinua-
tions due to liver enzyme abnormalities was observed in
4S (8 [0.36%] simvastatin vs 5 [0.22%] placebo)[23].
Among 32,145 patients who started the run-in period for
HPS, 2% (656) of patients with abnormal liver function
tests in blood collected at the screening visit were with-
drawn during the placebo phase. No patient who
attended the randomization visit failed to proceed to ran-
domization because of an abnormal liver function test
after taking 4–6 weeks of active simvastatin during the
run-in period, but 6 randomized patients were subse-
quently found to have ALT >3 × ULN in blood collected at
the randomization visit. None of these elevations per-
sisted on repeat testing when these patients were no
longer taking simvastatin (since all 6 had, by chance, been
allocated placebo) and none was discontinued from study
treatment. Consequently, the pre-randomization run-in
period in HPS is not likely to have biased the assessment
of the effects of 5 years of treatment with simvastatin 40
mg daily on the risks of clinical hepatitis. Consequently,
most regulatory agencies have now allowed the recom-
mendations in the prescribing information for simvasta-
tin to indicate that routine liver monitoring is not needed
for doses of simvastatin up to and including 40 mg daily.
It remains uncertain whether, these conclusions can be
extrapolated to simvastatin 80 mg daily (the maximal rec-
ommended dose of this drug), and this is now being
assessed as part of a large-scale direct randomized com-
parison of 80 mg versus 20 mg simvastatin daily[22,25].
Conclusion
The present results provide further evidence of the safety
of long-term treatment with simvastatin 40 mg daily. The
risk of myopathy was rare, with an incidence of less than
0.1% over 5 years, and there was no evidence that simvas-BMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
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tatin 40 mg daily causes clinical hepatitis. Routine moni-
toring of liver function tests during treatment with
simvastatin at daily doses up to 40 mg did not appear to
be of value, at least in patients with liver function tests
that were normal prior to starting treatment.
Competing interests
The Clinical Trial Service Unit has a staff policy of not
accepting honoraria or other payments from the pharma-
ceutical industry, except for the reimbursement of costs to
participate in scientific meetings. Coordinating centre
members of the writing committee (J Armitage, R Collins,
L Bowman, S Parish) have, therefore, only had such costs
reimbursed. J Tobert is a retired employee of Merck and
Co, holds stock options granted when he was an
employee, and has provided consultant services to Merck
and other companies with lipid-lowering products.
Authors' contributions
MRC/BHF Heart Protection Study Collaborative Group
Writing Committee-Jane Armitage, Louise Bowman, Rory
Collins, Sarah Parish and Jonathan Tobert
JA was involved in data collection, analysis and interpre-
tation, and drafted the manuscript. LB was involved in
data collection, analysis and interpretation, and drafting
of the manuscript. RC conceived and designed the study,
was involved in data collection, analysis and interpreta-
tion, and drafting of the manuscript. SP was involved in
data collection, analysis, validation and interpretation. JT
was involved in the study design and interpretation, and
drafted the manuscript. All authors provided comments
on and approved the final manuscript.
Steering Committee-R Collins (principal investigator), T
Meade (chairman), P Sleight (vice-chairman), J Armitage
(clinical coordinator), S Parish and R Peto (statisticians),
L Youngman (laboratory director), M Buxton, D de Bono
(deceased), C George, J Fuller, A Keech, A Mansfield, B
Pentecost, D Simpson, C Warlow; J McNamara and L
O'Toole (MRC observers).
Data Monitoring Committee-R Doll (chairman, deceased), L
Wilhelmsen (vice-chairman), K M Fox, C Hill, P Sander-
cock.
Collaborators-listed in reference 3.
Acknowledgements
The most important acknowledgment is to the participants in the study, and 
to the doctors, nurses and administrative staff in hospitals and general prac-
tices throughout the United Kingdom who assisted with its conduct. The 
study was funded by the UK Medical Research Council, the British Heart 
Foundation, Merck & Co (manufacturers of simvastatin) and Roche Vita-
mins Ltd (manufacturers of the vitamins).
References
1. Pedersen TR, Tobert JA: Simvastatin: a review.  Expert Opin Phar-
macother 2004, 5:2583-96.
2. Randomised trial of cholesterol lowering in 4444 patients
with coronary heart disease: the Scandinavian Simvastatin
Survival Study (4S).  Lancet 1994, 344:1383-9.
3. Heart Protection Study Collaborative Group: MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in
20,536 high-risk individuals: a randomised placebo-control-
led trial.  Lancet 2002, 360:7-22.
4. Heart Protection Study Collaborative Group: MRC/BHF Heart
Protection Study of cholesterol-lowering with simvastatin in
5963 people with diabetes: a randomised placebo-controlled
trial.  Lancet 2003, 361:2005-16.
5. Heart Protection Study Collaborative Group: Effects of choles-
terol-lowering with simvastatin on stroke and other major
vascular events in 20536 people with cerebrovascular dis-
ease or other high-risk conditions.  Lancet 2004, 363:757-67.
6. Heart Protection Study Collaborative Group: Randomized trial of
the effects of cholesterol-lowering with simvastatin on
peripheral vascular and other major vascular outcomes in
20,536 people with peripheral arterial disease and other
high-risk conditions.  Journal of Vascular Surgery 2007, 45:645-654.
7. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and
safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised
trials of statins.  Lancet 2005, 366:1267-78.
8. Heart Protection Study Collaborative Group: MRC/BHF Heart
Protection Study of cholesterol-lowering therapy and of
antioxidant vitamin supplementation in a wide range of
patients at increased risk of coronary heart disease death:
early safety and efficacy experience.  European Heart Journal
1999, 20:725-41.
9. Heart Protection Study Collaborative Group: The effects of cho-
lesterol lowering with simvastatin on cause-specific mortal-
ity and on cancer incidence in 20,536 high-risk people: a
randomised placebo-controlled trial.  BMC Med 2005, 3:6.
10. Heart Protection Study Collaborative Group: N-terminal Pro-B-
type natriuretic peptide, vascular disease risk, and choles-
terol reduction among 20,536 patients in the MRC/BHF
heart protection study.  Journal of the American College of Cardiology
2007, 49:311-9.
11. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA,
Leitersdorf E, Marz W, Reckless JP, Stein EA: Risk for myopathy
with statin therapy in high-risk patients.  Archives of Internal Med-
icine 2003, 163:553-64.
12. Thompson PD, Clarkson P, Karas RH: Statin-associated myopa-
thy.  JAMA 2003, 289:1681-90.
13. Law M, Rudnicka AR: Statin safety: a systematic review.  Ameri-
can Journal of Cardiology 2006, 97:52C-60C.
14. Tobert JA: Efficacy and long-term adverse effect pattern of
lovastatin.  American Journal of Cardiology 1988, 62:28J-34J.
15. Tobert JA: Lovastatin and beyond: the history of the HMG-
CoA reductase inhibitors.  Nat Rev Drug Discov 2003, 2:517-26.
16. Tolman KG: The liver and lovastatin.  American Journal of Cardiol-
ogy 2002, 89:1374-80.
17. Bays H: Statin safety: an overview and assessment of the data
– 2005.  American Journal of Cardiology 2006, 97:6C-26C.
18. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH: Screen-
ing for statin-related toxicity: the yield of transaminase and
creatine kinase measurements in a primary care setting.
Archives of Internal Medicine 2003, 163:688-92.
19. Heart Protection Study Collaborative Group: MRC/BHF Heart
Protection Study of antioxidant vitamin supplementation in
20,536 high-risk individuals: a randomised placebo-control-
led trial.  Lancet 2002, 360:23-33.
20. Maddrey WC: Drug-induced hepatotoxicity: 2005.  Journal of
Clinical Gastroenterology 2005, 39:S83-9.
21. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH: Estimating
the effect of the run-in on the power of the Physicians'
Health Study.  Statistics in Medicine 1991, 10:1585-93.
22. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I,
Lathrop M, Collins R: SLCO1B1 variants and statin-induced
myopathy – a genomewide study.  New England Journal of Medi-
cine 2008, 359:789-99.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Clinical Pharmacology 2009, 9:6 http://www.biomedcentral.com/1472-6904/9/6
Page 10 of 10
(page number not for citation purposes)
23. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J,
Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsson G,
Tobert JA, Wedel H, Wilhelmsen L: Safety and tolerability of
cholesterol lowering with simvastatin during 5 years in the
Scandinavian Simvastatin Survival Study.  Archives of Internal
Medicine 1996, 156:2085-92.
24. Amacher DE: Serum transaminase elevations as indicators of
hepatic injury following the administration of drugs.  Regul
Toxicol Pharmacol 1998, 27(2):119-30.
25. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R: Study of the
effectiveness of additional reductions in cholesterol and
homocysteine (SEARCH): characteristics of a randomized
trial among 12064 myocardial infarction survivors.  American
Heart Journal 2007, 154:815-23.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6904/9/6/prepub